Karuna Therapeutics - KRTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $259.38
  • Forecasted Upside: 31.98%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +5.32 (2.78%)

This chart shows the closing price for KRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Karuna Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRTX

Analyst Price Target is $259.38
▲ +31.98% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Karuna Therapeutics in the last 3 months. The average price target is $259.38, with a high forecast of $318.00 and a low forecast of $209.00. The average price target represents a 31.98% upside from the last price of $196.53.

This chart shows the closing price for KRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Karuna Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00Low
11/17/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$318.00Low
11/17/2023WedbushReiterated RatingOutperform ➝ Outperform$253.00Low
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$235.00 ➝ $225.00Low
11/3/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$332.00 ➝ $296.00Low
11/3/2023WedbushBoost TargetOutperform ➝ Outperform$250.00 ➝ $253.00Low
9/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00Low
9/8/2023Bank of AmericaLower TargetBuy ➝ Buy$304.00 ➝ $259.00Low
8/22/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$214.00Low
8/22/2023Wells Fargo & CompanyInitiated CoverageOverweight$225.00Low
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$280.00Low
8/4/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$249.00 ➝ $235.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00Low
8/4/2023MizuhoLower TargetBuy ➝ Buy$274.00 ➝ $258.00Low
7/20/2023Morgan StanleyInitiated CoverageOverweight$280.00Low
6/5/202358.comReiterated RatingMaintainsLow
6/5/2023JPMorgan Chase & Co.Lower Target$260.00 ➝ $250.00Low
5/8/2023MizuhoBoost Target$270.00 ➝ $274.00Low
3/28/2023HC WainwrightLower TargetBuy$320.00 ➝ $300.00Low
3/21/2023JMP SecuritiesReiterated RatingMarket Outperform$323.00Low
3/21/2023WedbushReiterated RatingOutperformLow
3/7/2023Cantor FitzgeraldInitiated CoverageNeutral$214.00Low
3/2/2023Wells Fargo & CompanyLower TargetOverweight$262.00 ➝ $257.00Low
2/1/2023HC WainwrightReiterated RatingBuy$320.00Low
1/27/2023UBS GroupInitiated CoverageNeutral$209.00Low
1/5/2023Piper SandlerInitiated CoverageOverweight$285.00Low
12/9/2022MizuhoLower TargetBuy$276.00 ➝ $270.00Low
11/4/2022Wells Fargo & CompanyLower TargetOverweight$264.00 ➝ $262.00Low
11/1/2022Loop CapitalInitiated CoverageBuy$288.00Low
9/29/2022Royal Bank of CanadaBoost Target$292.00 ➝ $293.00Low
9/13/2022Stifel NicolausBoost TargetBuy$260.00 ➝ $295.00Low
8/15/2022CitigroupBoost Target$280.00N/A
8/15/2022HC WainwrightBoost TargetBuy$160.00 ➝ $320.00Low
8/12/2022Royal Bank of CanadaBoost TargetOutperform$160.00 ➝ $292.00Low
8/12/2022GuggenheimBoost TargetBuy$200.00 ➝ $330.00Low
8/10/2022Wells Fargo & CompanyBoost TargetOverweight$186.00 ➝ $264.00Low
8/9/2022The Goldman Sachs GroupBoost TargetBuy$228.00 ➝ $278.00Low
8/9/2022MizuhoBoost TargetBuy$190.00 ➝ $276.00Low
8/9/2022Bank of AmericaBoost TargetBuy$160.00 ➝ $261.00Low
8/9/2022SVB LeerinkBoost TargetOutperform$170.00 ➝ $270.00Low
7/14/2022SVB LeerinkInitiated CoverageOutperform$170.00Low
6/28/2022JMP SecuritiesBoost TargetMarket Outperform$175.00 ➝ $190.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$202.00 ➝ $174.00Low
4/27/2022MizuhoBoost Target$178.00 ➝ $190.00High
3/31/2022Berenberg BankInitiated CoverageBuy$190.00High
3/8/2022Jefferies Financial GroupBoost TargetBuy$180.00 ➝ $183.00Medium
3/3/2022MizuhoLower TargetBuy$182.00 ➝ $178.00Medium
1/24/2022WedbushBoost TargetOutperform$167.00 ➝ $176.00High
11/8/2021OppenheimerBoost TargetOutperform$148.00 ➝ $175.00Low
11/5/2021MizuhoBoost TargetBuy$150.00 ➝ $182.00High
11/4/2021Stifel NicolausBoost TargetBuy$154.00 ➝ $185.00High
9/30/2021JPMorgan Chase & Co.Initiated CoverageOverweight$162.00High
8/30/2021CitigroupInitiated CoverageBuy$152.00Low
7/28/2021Jefferies Financial GroupInitiated CoverageBuy$158.00High
6/23/2021Royal Bank of CanadaBoost TargetOutperform$164.00 ➝ $173.00High
5/7/2021The Goldman Sachs GroupLower TargetBuy$192.00 ➝ $171.00Medium
4/26/2021HC WainwrightBoost TargetBuy$130.00 ➝ $160.00High
3/22/2021Bank of AmericaInitiated CoverageBuy$150.00High
3/4/2021MizuhoBoost TargetBuy$116.00 ➝ $150.00N/A
3/1/2021OppenheimerBoost TargetOutperform$135.00 ➝ $148.00Low
2/26/2021Maxim GroupReiterated RatingBuyLow
2/26/2021MizuhoBoost TargetBuy$116.00 ➝ $150.00High
2/26/2021JMP SecuritiesBoost TargetOutperform$122.00 ➝ $167.00High
2/9/2021Royal Bank of CanadaInitiated CoverageOutperform$160.00Low
1/5/2021William BlairReiterated RatingBuyN/A
12/17/2020OppenheimerInitiated CoverageBuy$135.00Medium
11/19/2020Maxim GroupInitiated CoverageBuy$150.00Medium
8/11/2020William BlairReiterated RatingBuyMedium
8/6/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $130.00Low
7/31/2020William BlairReiterated RatingBuyLow
7/29/2020HC WainwrightReiterated RatingBuyHigh
6/24/2020HC WainwrightReiterated RatingBuy$140.00High
6/24/2020OppenheimerBoost TargetPositive ➝ Outperform$125.00 ➝ $135.00Medium
6/23/2020MizuhoReiterated RatingBuy$116.00High
6/3/2020Stifel NicolausBoost TargetBuy$126.00 ➝ $135.00Low
6/2/2020WedbushBoost TargetOutperform$117.00 ➝ $126.00Low
6/1/2020The Goldman Sachs GroupBoost TargetBuy$115.00 ➝ $131.00Medium
5/28/2020HC WainwrightInitiated CoverageBuy$140.00Medium
5/8/2020MizuhoBoost TargetBuy$103.00 ➝ $116.00Medium
4/27/2020OppenheimerInitiated CoverageOutperform$125.00High
3/31/2020GuggenheimInitiated CoverageBuy$120.00Low
3/24/2020WedbushReiterated RatingOutperform$124.00High
3/24/2020MizuhoReiterated RatingBuy$120.00High
2/5/2020MizuhoInitiated CoverageBuy$120.00High
1/22/2020Wells Fargo & CompanyBoost TargetOverweight$106.00 ➝ $137.00Medium
1/9/2020JMP SecuritiesInitiated CoverageOutperform$122.00Medium
12/19/2019Stifel NicolausInitiated CoverageBuy$126.00High
12/12/2019William BlairInitiated CoverageOutperform$105.00High
11/21/2019WedbushBoost TargetPositive ➝ Outperform$38.00 ➝ $134.00High
11/18/2019The Goldman Sachs GroupBoost TargetBuy ➝ Positive$35.00 ➝ $109.00High
11/12/2019WedbushReiterated RatingBuy$38.00Low
8/9/2019WedbushReiterated RatingOutperform$38.00High
7/23/2019WedbushInitiated CoverageOutperform ➝ Outperform$38.00Medium
7/23/2019CitigroupInitiated CoverageBuy ➝ Buy$28.00High
7/23/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$29.00High
7/23/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$34.00High
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 8 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 14 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 13 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Karuna Therapeutics logo
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $196.53
Low: $188.07
High: $196.53

50 Day Range

MA: $174.52
Low: $161.01
High: $196.53

52 Week Range

Now: $196.53
Low: $158.38
High: $245.00


227,697 shs

Average Volume

220,056 shs

Market Capitalization

$7.42 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Karuna Therapeutics?

The following equities research analysts have issued reports on Karuna Therapeutics in the last year: 58.com Inc., Bank of America Co., Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Royal Bank of Canada, The Goldman Sachs Group, Inc., UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for KRTX.

What is the current price target for Karuna Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Karuna Therapeutics in the last year. Their average twelve-month price target is $259.38, suggesting a possible upside of 32.0%. JMP Securities has the highest price target set, predicting KRTX will reach $318.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $209.00 for Karuna Therapeutics in the next year.
View the latest price targets for KRTX.

What is the current consensus analyst rating for Karuna Therapeutics?

Karuna Therapeutics currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KRTX.

What other companies compete with Karuna Therapeutics?

How do I contact Karuna Therapeutics' investor relations team?

Karuna Therapeutics' physical mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company's listed phone number is (857) 449-2244 and its investor relations email address is investor[email protected]. The official website for Karuna Therapeutics is karunatx.com. Learn More about contacing Karuna Therapeutics investor relations.